# QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

> **NCT07009145** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qianfoshan Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Unresectable Colorectal Cancer
- Metastatic Colorectal Cancer (CRC)
- MSI-H/dMMR Colorectal Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07009145
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009145, "QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07009145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*